122 related articles for article (PubMed ID: 38123744)
1. Development, Characterization, and Radiation Dosimetry Studies of
Kim J; Donnelly DJ; Tran T; Pena A; Shorts AO; Petrone TV; Zhang Y; Boy KM; Scola PM; Tenney DJ; Poss MA; Soars MG; Bonacorsi SJ; Cole EL; Grootendorst DJ; Chow PL; Meanwell NA; Du S
Mol Imaging Biol; 2024 Apr; 26(2):301-309. PubMed ID: 38123744
[TBL] [Abstract][Full Text] [Related]
2. The discovery and evaluation of [
Donnelly DJ; Kim J; Tran T; Scola PM; Tenney D; Pena A; Petrone T; Zhang Y; Boy KM; Poss MA; Cole EL; Soars MG; Johnson BM; Cohen D; Batalla D; Chow PL; Shorts AO; Du S; Meanwell NA; Bonacorsi SJ
Eur J Nucl Med Mol Imaging; 2024 Mar; 51(4):978-990. PubMed ID: 38049658
[TBL] [Abstract][Full Text] [Related]
3. Preclinical and first-in-human evaluation of
Zhou M; Wang X; Chen B; Xiang S; Rao W; Zhang Z; Liu H; Fang J; Yin X; Deng P; Zhang X; Hu S
Eur J Nucl Med Mol Imaging; 2022 Nov; 49(13):4312-4324. PubMed ID: 35831714
[TBL] [Abstract][Full Text] [Related]
4. In Vivo Evaluation and Dosimetry Estimate for a High Affinity Affibody PET Tracer Targeting PD-L1.
Rubins DJ; Meng X; McQuade P; Klimas M; Getty K; Lin SA; Connolly BM; O'Malley SS; Haley H; Purcell M; Gantert L; Holahan M; Lindgren J; Eklund P; Ekblad C; Frejd FY; Hostetler ED; González Trotter DE; Evelhoch JL
Mol Imaging Biol; 2021 Apr; 23(2):241-249. PubMed ID: 33098025
[TBL] [Abstract][Full Text] [Related]
5.
Cheng Y; Shi D; Xu Z; Gao Z; Si Z; Zhao Y; Ye R; Fu Z; Fu W; Yang T; Xiu Y; Lin Q; Cheng D
Mol Pharm; 2022 Oct; 19(10):3551-3562. PubMed ID: 35244407
[TBL] [Abstract][Full Text] [Related]
6. First-in-Humans Evaluation of a PD-L1-Binding Peptide PET Radiotracer in Non-Small Cell Lung Cancer Patients.
Zhou X; Jiang J; Yang X; Liu T; Ding J; Nimmagadda S; Pomper MG; Zhu H; Zhao J; Yang Z; Li N
J Nucl Med; 2022 Apr; 63(4):536-542. PubMed ID: 34326125
[No Abstract] [Full Text] [Related]
7. Development of [
Lesniak WG; Mease RC; Chatterjee S; Kumar D; Lisok A; Wharram B; Kalagadda VR; Emens LA; Pomper MG; Nimmagadda S
Mol Imaging; 2019; 18():1536012119852189. PubMed ID: 31187691
[TBL] [Abstract][Full Text] [Related]
8. A novel
Ge S; Zhang B; Li J; Shi J; Jia T; Wang Y; Chen Z; Sang S; Deng S
Bioorg Chem; 2023 Nov; 140():106785. PubMed ID: 37639759
[TBL] [Abstract][Full Text] [Related]
9. Immuno-PET imaging of PD-L1 expression in patient-derived lung cancer xenografts with [
Liu Q; Wang X; Yang Y; Wang C; Zou J; Lin J; Qiu L
Quant Imaging Med Surg; 2022 Jun; 12(6):3300-3313. PubMed ID: 35655844
[TBL] [Abstract][Full Text] [Related]
10. Practical Immuno-PET Radiotracer Design Considerations for Human Immune Checkpoint Imaging.
Mayer AT; Natarajan A; Gordon SR; Maute RL; McCracken MN; Ring AM; Weissman IL; Gambhir SS
J Nucl Med; 2017 Apr; 58(4):538-546. PubMed ID: 27980047
[TBL] [Abstract][Full Text] [Related]
11. In vivo characterization of PD-L1 expression in breast cancer by immuno-PET with
Li M; Ehlerding EB; Jiang D; Barnhart TE; Chen W; Cao T; Engle JW; Cai W
Am J Transl Res; 2020; 12(5):1862-1872. PubMed ID: 32509182
[TBL] [Abstract][Full Text] [Related]
12. PET Imaging of Tumor PD-L1 Expression with a Highly Specific Nonblocking Single-Domain Antibody.
Lv G; Sun X; Qiu L; Sun Y; Li K; Liu Q; Zhao Q; Qin S; Lin J
J Nucl Med; 2020 Jan; 61(1):117-122. PubMed ID: 31253743
[TBL] [Abstract][Full Text] [Related]
13. Dose escalation biodistribution, positron emission tomography/computed tomography imaging and dosimetry of a highly specific radionuclide-labeled non-blocking nanobody.
Yang Y; Wang C; Wang Y; Sun Y; Huang X; Huang M; Xu H; Fan H; Chen D; Zhao F
EJNMMI Res; 2021 Oct; 11(1):113. PubMed ID: 34718889
[TBL] [Abstract][Full Text] [Related]
14. Development of a 68Gallium-Labeled D-Peptide PET Tracer for Imaging Programmed Death-Ligand 1 Expression.
Zhang L; Zhang S; Wu W; Wang X; Shen J; Wang D; Hu K; Zhang MR; Wang F; Wang R
J Vis Exp; 2023 Feb; (192):. PubMed ID: 36806629
[TBL] [Abstract][Full Text] [Related]
15. Linear Peptide-Based PET Tracers for Imaging PD-L1 in Tumors.
Zhang L; Zhang S; Wu J; Wang Y; Wu Y; Sun X; Wang X; Shen J; Xie L; Zhang Y; Zhang H; Hu K; Wang F; Wang R; Zhang MR
Mol Pharm; 2023 Aug; 20(8):4256-4267. PubMed ID: 37368947
[TBL] [Abstract][Full Text] [Related]
16. Preclinical Study of a Fully Human Anti-PD-L1 Antibody as a Theranostic Agent for Cancer Immunotherapy.
Xu M; Han Y; Liu G; Xu Y; Duan D; Liu H; Du F; Luo P; Liu Z
Mol Pharm; 2018 Oct; 15(10):4426-4433. PubMed ID: 30133286
[TBL] [Abstract][Full Text] [Related]
17. PD-L1 PET/CT Imaging with Radiolabeled Durvalumab in Patients with Advanced-Stage Non-Small Cell Lung Cancer.
Smit J; Borm FJ; Niemeijer AN; Huisman MC; Hoekstra OS; Boellaard R; Oprea-Lager DE; Vugts DJ; van Dongen GAMS; de Wit-van der Veen BJ; Thunnissen E; Smit EF; de Langen AJ
J Nucl Med; 2022 May; 63(5):686-693. PubMed ID: 34385342
[TBL] [Abstract][Full Text] [Related]
18. Immuno-PET Imaging of
Li D; Cheng S; Zou S; Zhu D; Zhu T; Wang P; Zhu X
Mol Pharm; 2018 Apr; 15(4):1674-1681. PubMed ID: 29502426
[TBL] [Abstract][Full Text] [Related]
19. One-step radiosynthesis and initial evaluation of a small molecule PET tracer for PD-L1 imaging.
Miao Y; Lv G; Chen Y; Qiu L; Xie M; Lin J
Bioorg Med Chem Lett; 2020 Dec; 30(24):127572. PubMed ID: 32979488
[TBL] [Abstract][Full Text] [Related]
20. Negative Correlation Between
Wu L; Liu J; Wang S; Bai M; Wu M; Gao Z; Li J; Yu J; Liu J; Meng X
Front Endocrinol (Lausanne); 2022; 13():913631. PubMed ID: 35846323
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]